| Anti-CCR5 antibody |
Ref |
Study |
Immunogen/Vector |
Adjuvant//Route/ Schedule |
Biological features |
Limits |
Natural ECL1
Abs |
[75, 80, 83, 84, 86] |
ESN and LTNP sera. |
Natural Ags ? |
Low dose Ags presented by mucosal route ? |
Inhibition of MIP-1beta chemotaxis.
Binding to native CCR5 on PBMC.
CCR5 internalization.
Block of HIV transcytosis .
Block of R5-HIV isolates from A, B, C, E clades |
Natural, uncommon. |
| Natural Nt/ECL2 Abs |
[76-78, 85] |
Healthy donors
Delta32+ ESN
Delta32+
CCR5-
HIV+ patients |
Natural Ags? |
Allo Ags exposure ? |
Competition for chemokine binding.
Binding to native CCR5 on transfected or PBMC.
Block of R5-HIV laboratory and primary isolates. |
Natural response observed in healthy HIVexposed or in chronic HIV pz.
Not all Abs internalize CCR5 |
| Anti-CCR5 humanized mAbs |
[68-71] |
Passive immunization clinical trial |
PRO140 HGS001 |
IV infusion in HIV-positive patients |
Well-tollerated, no toxicity. |
IM infusion.
Immune responses to therapeutic Abs. |
